Michael Blash

Accomplished and enthusiastic senior-level business leader who applies the power of outstanding communications and marketing to deliver value for investigational products, inline brands and companies. He has nearly 25 years of biopharmaceutical industry experience at The Medicines Company (NASDAQ: MDCO), Merck (NYSE: MRK) and Zeneca Pharmaceuticals, as well as with communications consultancies. His efforts with $MDCO contributed to >300% stock appreciation and $9.7B acquisition by Novartis (NYSE: NVS) at a 57% premium to the unaffected one-week average share price.